Distinct Profiles of Fecal Volatile Organic Compounds Discriminate Ulcerative Colitis Patients With an Ileoanal Pouch From Those With an Intact Colon
- PMID: 40018833
- PMCID: PMC11962224
- DOI: 10.1002/mnfr.70003
Distinct Profiles of Fecal Volatile Organic Compounds Discriminate Ulcerative Colitis Patients With an Ileoanal Pouch From Those With an Intact Colon
Abstract
Fecal volatile organic compounds (VOCs) offer insights into gut microbiota function that may drive the pathogenesis of ulcerative colitis (UC). This cross-sectional study aimed to compare dietary intake and VOC patterns in UC patients with an ileoanal pouch compared to those with an intact colon. Seven-day food records and fecal samples were collected from UC patients with an intact colon (n = 28) or an ileoanal pouch (n = 11). Fecal VOC profiles were analyzed using gas chromatography-mass spectrometry. Dietary intake in both groups was largely similar. The mean Jaccard similarity index of VOC was 0.55 (95% CI:0.53, 0.56) in the pouch compared with 0.48 (0.47, 0.49) in the colon group (p < 0.01). A lower proportion of VOC classes was detected in the pouch, including sulfide (9% vs. 57%; p < 0.01), branched-chain fatty acids (BCFAs; 45%-64% vs. 93%-96%; p < 0.01), and ketones (45%-64% vs. 93%-96%; p < 0.01), along with a higher proportion of butyric acid (91% vs. 29%; p < 0.001). Unrelated to diet, VOC profiles show less functional diversity, reduced protein and greater carbohydrate fermentation, and altered production of secondary metabolites in the UC-pouch compared with the intact colon. These differences in the metabolic environment of the gut microbiota provide insights into pathogenesis and suggest that microbial-targeted interventions should be tailored accordingly.
Keywords: diet; ileoanal pouch; metabolomics; ulcerative colitis; volatile organic compounds.
© 2025 The Author(s). Molecular Nutrition & Food Research published by Wiley‐VCH GmbH.
Conflict of interest statement
RVB has received grant/research support/speaker fees from AbbVie, Ferring, Janssen, Shire, Takeda, GSK, and Emerge Health; and is a shareholder in Biomebank. PRG has served as consultant or advisory board member for Anatara, Atmo Biosciences, Topas, and Comvita. He has received research grants for investigator‐driven studies from Atmo Biosciences and Mindset Health and speaker honoraria from Dr Falk Pharma and Mindset Health. He holds shares in Atmo Biosciences. CKY has received research grants for investigator‐driven studies from Atmo Biosciences and honoraria from Viatris, Yakult Australia. Alice S. Day has received research support for investigator‐led studies from ECCO, The Hospital Research Foundation and GUTSY Group. Alice S. Day has also received consulting fees or honoraria from BiomeBank, AbbVie, Ferring, and Janssen. KG, ZMA, and CP have no disclosures to declare in relation to this work. The Department of Gastroenterology, which CKY, PRG, ZMA are from, financially benefits from the sales of a digital application, booklets, and online courses on the FODMAP diet.
Figures



References
-
- Spinelli A., Bonovas S., Burisch J., et al., “ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment,” Journal of Crohn's and Colitis 16 (2021): 179–189. - PubMed
-
- Christl S. U. and Scheppach W., “Metabolic Consequences of Total Colectomy,” Scandinavian Journal of Gastroenterology Supplement 222 (1997): 20–24. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical